fenofibrate has been researched along with Chemical and Drug Induced Liver Injury in 44 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes." | 5.34 | Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard. ( Cai, G; Du, L; Nie, Y; Xie, W; Zhang, Y, 2007) |
| " The objective of this study was to evaluate the efficacy and safety profile of fenofibrate as an add-on in patients with dyslipidemia despite receiving statin therapy." | 5.22 | Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. ( Chen, H; Cheng, X; Cui, S; Dai, Y; Dong, Y; Fu, G; Gong, H; Hu, T; Huang, H; Li, X; Li, Z; Liao, Y; Lin, L; Liu, J; Liu, X; Sun, Y; Tong, Q; Wang, D; Wang, F; Wang, G; Wei, P; Xie, Q; Yan, J; Yan, L; Yan, Y; Yin, Y; Zhao, S, 2016) |
| "The acute severe DILI occurred within only 4 days after fenofibrate initial treatment for hypertriglyceridemia." | 3.96 | Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database. ( Chen, L; Liu, S; Ma, S; Sun, H; Wang, Q; Yang, P, 2020) |
| "An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis." | 3.72 | Risk of adverse events with fibrates. ( Alsheikh-Ali, AA; Karas, RH; Kuvin, JT, 2004) |
| "Statin monotherapy is generally well tolerated, with a low frequency of adverse events." | 2.42 | Safety of statins: focus on clinical pharmacokinetics and drug interactions. ( Bellosta, S; Corsini, A; Paoletti, R, 2004) |
| "Then fenofibrate 25 mg/kg was orally administrated to mice twice/day for 14 days." | 1.62 | Fenofibrate reverses liver fibrosis in cholestatic mice induced by alpha-naphthylisothiocyanate. ( Dai, M; Li, S; Liu, A; Lu, Z; Luo, J; Luo, Y; Qiu, J; Yang, J; Zheng, X, 2021) |
| "Post-treatment with fenofibrate significantly inhibits APAP-induced hepatotoxicity, as evidenced by decreased serum ALT and AST levels and hepatic necrosis in liver tissue as well as increased the surviving rate in response to APAP overdose, whereas this protective effect of fenofibrate is largely attenuated in FGF21 KO mice." | 1.48 | FGF21 mediates the protective effect of fenofibrate against acetaminophen -induced hepatotoxicity via activating autophagy in mice. ( Li, Q; Li, X; Pan, X; Pan, Y; Xiong, R; Yang, S; Zhang, S; Zhang, Y; Zheng, J, 2018) |
| "Fenofibrate is a commonly used hypolipidemic associated with rare instances of hepatotoxicity, and routine liver biochemistry monitoring is recommended." | 1.46 | Identification and Characterization of Fenofibrate-Induced Liver Injury. ( Ahmad, J; Barnhart, H; Chalasani, N; Cirulli, ET; Fontana, RJ; Hayashi, PH; Hoofnagle, JH; Kleiner, DE; Odin, JA, 2017) |
| "Fenofibrate has a well-known efficacy to reduce cholesterol and triglycerides." | 1.43 | Hepatotoxic effects of fenofibrate in spontaneously hypertensive rats expressing human C-reactive protein. ( Kazdová, L; Kůdela, M; Landa, V; Malínská, H; Marková, I; Mlejnek, P; Oliyarnyk, O; Pravenec, M; Šilhavý, J; Šimáková, M; Škop, V; Trnovská, J; Zídek, V, 2016) |
| "Hyperlipidemia is referred to as hypercholesterolemia, hypertriglyceridemia, or both in combined hyperlipidemia." | 1.39 | Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture. ( Jia, ZH; Ko, KM; Pan, SY; Sun, N; Wang, XY; Yu, Q; Yu, ZL; Zhang, Y; Zhu, PL, 2013) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
| " According to the detected ethanol toxic response marked by reduced cell viability, 3D cultured hepatocytes in gel entrapment were suggested to be better than 2D hepatocyte in monolayer, but the cultures in either William's Medium E or DMEM exhibited comparable sensitivity to ethanol toxicity." | 1.36 | Establishment of a methodology for investigating protectants against ethanol-induced hepatotoxicity. ( Meng, Q; Ruan, X; Shen, C, 2010) |
| " We reviewed gemfibrozil- and fenofibrate-associated adverse event reports (AERs) submitted to the US Food and Drug Administration over a 5-year period." | 1.35 | Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. ( Alsheikh-Ali, AA; Holoshitz, N; Karas, RH, 2008) |
| " In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes." | 1.34 | Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard. ( Cai, G; Du, L; Nie, Y; Xie, W; Zhang, Y, 2007) |
| "Fenofibrate was discontinued immediately." | 1.32 | Fenofibrate-induced acute cholestatic hepatitis. ( Chang, FY; Chen, TS; Ho, CY; Kuo, TH; Lee, SD; Tsay, SH, 2004) |
| "Fenofibrate withdrawal was rapidly followed by favorable outcome." | 1.28 | [Fenofibrate-induced acute hepatitis with pseudo-cholangitis]. ( Ducreux, M; Etienne, JP; Lelouch, S; Pelletier, G; Sinico, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.82) | 18.7374 |
| 1990's | 5 (11.36) | 18.2507 |
| 2000's | 12 (27.27) | 29.6817 |
| 2010's | 21 (47.73) | 24.3611 |
| 2020's | 3 (6.82) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Greene, N | 1 |
| Fisk, L | 1 |
| Naven, RT | 1 |
| Note, RR | 1 |
| Patel, ML | 1 |
| Pelletier, DJ | 1 |
| Morgan, RE | 2 |
| Trauner, M | 1 |
| van Staden, CJ | 2 |
| Lee, PH | 1 |
| Ramachandran, B | 1 |
| Eschenberg, M | 1 |
| Afshari, CA | 2 |
| Qualls, CW | 1 |
| Lightfoot-Dunn, R | 1 |
| Hamadeh, HK | 2 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 2 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Aleo, MD | 1 |
| Luo, Y | 2 |
| Swiss, R | 1 |
| Bonin, PD | 1 |
| Potter, DM | 1 |
| Will, Y | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Ma, S | 1 |
| Liu, S | 1 |
| Wang, Q | 1 |
| Yang, P | 1 |
| Sun, H | 1 |
| Lu, Z | 1 |
| Li, S | 1 |
| Luo, J | 1 |
| Dai, M | 1 |
| Zheng, X | 1 |
| Qiu, J | 1 |
| Yang, J | 1 |
| Liu, A | 1 |
| He, Y | 1 |
| Qin, MZ | 1 |
| Chen, YW | 1 |
| Zhao, Q | 1 |
| Yang, R | 1 |
| Wang, J | 1 |
| Hu, DD | 1 |
| Li, F | 1 |
| Ahmad, J | 1 |
| Odin, JA | 1 |
| Hayashi, PH | 2 |
| Chalasani, N | 2 |
| Fontana, RJ | 2 |
| Barnhart, H | 1 |
| Cirulli, ET | 2 |
| Kleiner, DE | 1 |
| Hoofnagle, JH | 1 |
| Zhang, Y | 4 |
| Pan, Y | 1 |
| Xiong, R | 1 |
| Zheng, J | 1 |
| Li, Q | 1 |
| Zhang, S | 1 |
| Li, X | 2 |
| Pan, X | 1 |
| Yang, S | 1 |
| Chan, JCY | 1 |
| Soh, ACK | 1 |
| Kioh, DYQ | 1 |
| Li, J | 1 |
| Verma, C | 1 |
| Koh, SK | 1 |
| Beuerman, RW | 1 |
| Zhou, L | 1 |
| Chan, ECY | 1 |
| Pan, SY | 1 |
| Jia, ZH | 1 |
| Yu, Q | 1 |
| Wang, XY | 1 |
| Sun, N | 1 |
| Zhu, PL | 1 |
| Yu, ZL | 1 |
| Ko, KM | 1 |
| Guo, H | 1 |
| Hassan, HM | 1 |
| Ding, PP | 1 |
| Su, Y | 1 |
| Song, Y | 1 |
| Wang, T | 1 |
| Sun, L | 1 |
| Zhang, L | 1 |
| Jiang, Z | 1 |
| Zhao, S | 1 |
| Wang, F | 1 |
| Dai, Y | 1 |
| Lin, L | 1 |
| Tong, Q | 1 |
| Liao, Y | 1 |
| Yin, Y | 1 |
| Wang, G | 1 |
| Yan, Y | 1 |
| Wang, D | 1 |
| Wei, P | 1 |
| Cheng, X | 1 |
| Xie, Q | 1 |
| Sun, Y | 1 |
| Fu, G | 1 |
| Huang, H | 1 |
| Dong, Y | 1 |
| Liu, J | 1 |
| Yan, J | 1 |
| Yan, L | 1 |
| Cui, S | 1 |
| Liu, X | 1 |
| Li, Z | 1 |
| Chen, H | 1 |
| Hu, T | 1 |
| Gong, H | 1 |
| Škop, V | 1 |
| Trnovská, J | 1 |
| Oliyarnyk, O | 1 |
| Marková, I | 1 |
| Malínská, H | 1 |
| Kazdová, L | 1 |
| Zídek, V | 1 |
| Landa, V | 1 |
| Mlejnek, P | 1 |
| Šimáková, M | 1 |
| Kůdela, M | 1 |
| Pravenec, M | 1 |
| Šilhavý, J | 1 |
| Nicoletti, P | 1 |
| Aithal, GP | 1 |
| Bjornsson, ES | 1 |
| Andrade, RJ | 1 |
| Sawle, A | 1 |
| Arrese, M | 1 |
| Barnhart, HX | 1 |
| Bondon-Guitton, E | 1 |
| Bessone, F | 1 |
| Carvajal, A | 1 |
| Cascorbi, I | 1 |
| Conforti, A | 1 |
| Coulthard, SA | 1 |
| Daly, MJ | 1 |
| Day, CP | 1 |
| Dillon, JF | 1 |
| Grove, JI | 1 |
| Hallberg, P | 1 |
| Hernández, N | 1 |
| Ibáñez, L | 1 |
| Kullak-Ublick, GA | 1 |
| Laitinen, T | 1 |
| Larrey, D | 1 |
| Lucena, MI | 1 |
| Maitland-van der Zee, AH | 1 |
| Martin, JH | 1 |
| Molokhia, M | 1 |
| Pirmohamed, M | 1 |
| Powell, EE | 1 |
| Qin, S | 1 |
| Serrano, J | 1 |
| Stephens, C | 1 |
| Stolz, A | 1 |
| Wadelius, M | 1 |
| Watkins, PB | 1 |
| Floratos, A | 1 |
| Shen, Y | 1 |
| Nelson, MR | 1 |
| Urban, TJ | 1 |
| Daly, AK | 1 |
| Tazuke, Y | 1 |
| Teitelbaum, DH | 1 |
| Hajdu, D | 1 |
| Aiglová, K | 1 |
| Vinklerová, I | 1 |
| Urbánek, K | 1 |
| Ruan, X | 1 |
| Shen, C | 1 |
| Meng, Q | 1 |
| Lee, SH | 1 |
| Cho, KI | 1 |
| Kim, JY | 1 |
| Ahn, YK | 1 |
| Rha, SW | 1 |
| Kim, YJ | 1 |
| Choi, YS | 1 |
| Choi, SW | 1 |
| Jeon, DW | 1 |
| Min, PK | 1 |
| Choi, DJ | 1 |
| Baek, SH | 1 |
| Kim, KS | 1 |
| Byun, YS | 1 |
| Jang, Y | 1 |
| Pichon, N | 1 |
| Vincensini, JF | 1 |
| Rozière, A | 1 |
| Labrousse, F | 1 |
| Sautereau, D | 1 |
| Pillegand, B | 1 |
| Bellosta, S | 1 |
| Paoletti, R | 1 |
| Corsini, A | 1 |
| Ho, CY | 1 |
| Kuo, TH | 1 |
| Chen, TS | 1 |
| Tsay, SH | 1 |
| Chang, FY | 1 |
| Lee, SD | 1 |
| Alsheikh-Ali, AA | 2 |
| Kuvin, JT | 1 |
| Karas, RH | 2 |
| Xie, W | 1 |
| Nie, Y | 1 |
| Du, L | 1 |
| Cai, G | 1 |
| Yang, Q | 1 |
| Nagano, T | 1 |
| Shah, Y | 1 |
| Cheung, C | 1 |
| Ito, S | 1 |
| Gonzalez, FJ | 1 |
| Holoshitz, N | 1 |
| Thulin, P | 1 |
| Rafter, I | 1 |
| Stockling, K | 1 |
| Tomkiewicz, C | 1 |
| Norjavaara, E | 1 |
| Aggerbeck, M | 1 |
| Hellmold, H | 1 |
| Ehrenborg, E | 1 |
| Andersson, U | 1 |
| Cotgreave, I | 1 |
| Glinghammar, B | 1 |
| Vachon, JM | 1 |
| Bernard, PH | 1 |
| Lamouliatte, H | 1 |
| Le Bail, B | 1 |
| Bioulac-Sage, P | 1 |
| Quinton, A | 1 |
| Balabaud, C | 1 |
| Rouhier, ML | 1 |
| Rifflet, H | 1 |
| Rifflet, I | 1 |
| Oberti, F | 1 |
| Vuillemin, E | 1 |
| Chevailler, A | 1 |
| Calès, P | 1 |
| Ganne-Carrié, N | 1 |
| de Leusse, A | 1 |
| Guettier, C | 1 |
| Castera, L | 1 |
| Levecq, H | 1 |
| Bertrand, HJ | 1 |
| Plumet, Y | 1 |
| Trinchet, JC | 1 |
| Beaugrand, M | 1 |
| Fartoux-Heymann, L | 1 |
| Narcy-Lambare, B | 1 |
| Labayle, D | 1 |
| Fischer, D | 1 |
| Hayakawa, T | 1 |
| Hayashi, A | 1 |
| Miyakawa, M | 1 |
| Shimoyama, K | 1 |
| Sekiya, S | 1 |
| Sekiguchi, M | 1 |
| Inotsume, N | 1 |
| Bravo, ML | 1 |
| Azagra, R | 1 |
| Aguyé, A | 1 |
| Freixas, M | 1 |
| Lelouch, S | 1 |
| Pelletier, G | 1 |
| Sinico, M | 1 |
| Ducreux, M | 1 |
| Etienne, JP | 1 |
| Migneco, G | 1 |
| Mascarella, A | 1 |
| La Ferla, A | 1 |
| Attianese, R | 1 |
| Massen, H | 1 |
| Furet, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01414803] | Phase 4 | 180 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Liver Injury by Statins in Coronary Heart Disease (CHD) Patients With History of Hepatitis B Virus (HBV) Infection[NCT02808299] | 600 participants (Anticipated) | Observational | 2016-12-31 | Not yet recruiting | |||
| A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073] | 79 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fenofibrate and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
2 trials available for fenofibrate and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment.
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrat | 2016 |
Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia.
Topics: Aged; Asian People; Biomarkers; Blood Glucose; Blood Urea Nitrogen; Cardiovascular Diseases; Chemica | 2012 |
40 other studies available for fenofibrate and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2014 |
Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database.
Topics: Aged; Chemical and Drug Induced Liver Injury; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidem | 2020 |
Fenofibrate reverses liver fibrosis in cholestatic mice induced by alpha-naphthylisothiocyanate.
Topics: 1-Naphthylisothiocyanate; Actins; Animals; Apoptosis Regulatory Proteins; Chemical and Drug Induced | 2021 |
Liver injury caused by fenofibrate within 48 h after first administration: a case report.
Topics: Chemical and Drug Induced Liver Injury; Fenofibrate; Humans; Liver Diseases; Male; Middle Aged | 2021 |
PPARα activation protects against cholestatic liver injury.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Disease Models, Animal; | 2017 |
Identification and Characterization of Fenofibrate-Induced Liver Injury.
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; Fenofibrate; HLA-A Antigens; Humans; Hypolipi | 2017 |
FGF21 mediates the protective effect of fenofibrate against acetaminophen -induced hepatotoxicity via activating autophagy in mice.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Autophagy; Chemical and Drug Induced Liver Injury; | 2018 |
Reactive Metabolite-induced Protein Glutathionylation: A Potentially Novel Mechanism Underlying Acetaminophen Hepatotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetaminophen; Animals; Carnitine O-Palmitoyltransfera | 2018 |
Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture.
Topics: Administration, Oral; Animals; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Cholest | 2013 |
Pyrazinamide induced hepatic injury in rats through inhibiting the PPARα pathway.
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Down-Regulation; Female; Fen | 2016 |
Hepatotoxic effects of fenofibrate in spontaneously hypertensive rats expressing human C-reactive protein.
Topics: Adipose Tissue; Animals; C-Reactive Protein; Chemical and Drug Induced Liver Injury; Fenofibrate; Gl | 2016 |
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.
Topics: Alleles; Antidepressive Agents; Antifungal Agents; Chemical and Drug Induced Liver Injury; Chromosom | 2017 |
Alteration of canalicular transporters in a mouse model of total parenteral nutrition.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2009 |
Acute cholestatic hepatitis induced by fenofibrate.
Topics: Acute Disease; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Female; Fenofibrat | 2009 |
Establishment of a methodology for investigating protectants against ethanol-induced hepatotoxicity.
Topics: Animals; Antioxidants; Cell Culture Techniques; Cell Survival; Cells, Cultured; Chemical and Drug In | 2010 |
[Acute cytolytic and cholestatic hepatitis induced by fenofibrate].
Topics: Acute Disease; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Fenofibrate; Human | 2003 |
Fenofibrate-induced acute cholestatic hepatitis.
Topics: Acute Disease; Chemical and Drug Induced Liver Injury; Cholestasis; Fenofibrate; Humans; Hypolipidem | 2004 |
Risk of adverse events with fibrates.
Topics: Aged; Chemical and Drug Induced Liver Injury; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidem | 2004 |
Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard.
Topics: Animals; Antioxidants; Ascorbic Acid; Blood Glucose; Chemical and Drug Induced Liver Injury; Cholest | 2007 |
The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha.
Topics: Animals; Antimetabolites; Blotting, Northern; Bromodeoxyuridine; Cell Proliferation; Chemical and Dr | 2008 |
Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Databases, Factual; | 2008 |
PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes.
Topics: Adult; Alanine Transaminase; Biomarkers; Chemical and Drug Induced Liver Injury; Chromatin; Electrop | 2008 |
[Hepatitis caused by procetofen].
Topics: Chemical and Drug Induced Liver Injury; Cholestyramine Resin; Female; Fenofibrate; gamma-Glutamylcyc | 1980 |
[Chronic active hepatitis associated with antinuclear antibodies induced by fenofibrate].
Topics: Antibodies, Antinuclear; Blood Chemical Analysis; Chemical and Drug Induced Liver Injury; Chemical a | 1994 |
[Painful acute liver involvement related to ingestion of fenofibrate].
Topics: Acute Disease; Chemical and Drug Induced Liver Injury; Female; Fenofibrate; Humans; Hypolipidemic Ag | 1996 |
[Autoimmune hepatitis induced by fibrates].
Topics: Aged; Autoimmune Diseases; Chemical and Drug Induced Liver Injury; Clofibric Acid; Female; Fenofibra | 1998 |
[Acute hepatitis and drug dermatitis due to fenofibrate (Secalip)].
Topics: Acute Disease; Adult; Alanine Transaminase; Bilirubin; Biopsy; Chemical and Drug Induced Liver Injur | 2001 |
[Studies on the risk factors for fenofibrate-induced elevation of liver function tests].
Topics: Aged; Alkaline Phosphatase; Body Mass Index; Chemical and Drug Induced Liver Injury; Female; Fenofib | 2002 |
[Acute hepatitis: an adverse reaction to fenofibrate treatment].
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Fenofibrate; Humans; Male | 1992 |
[Fenofibrate-induced acute hepatitis with pseudo-cholangitis].
Topics: Abdominal Pain; Acute Disease; Aged; Chemical and Drug Induced Liver Injury; Eosinophilia; Fenofibra | 1992 |
[Clofibrate hepatitis. A case report].
Topics: Chemical and Drug Induced Liver Injury; Clofibrate; Female; Fenofibrate; Humans; Middle Aged; Time F | 1986 |
[Hepatitis caused by fenofibrate].
Topics: Aged; Chemical and Drug Induced Liver Injury; Fenofibrate; Humans; Hypolipidemic Agents; Propionates | 1986 |